156 related articles for article (PubMed ID: 25147612)
1. Modulation of Activity Profiles for Largazole-Based HDAC Inhibitors through Alteration of Prodrug Properties.
Salvador LA; Park H; Al-Awadhi FH; Liu Y; Kim B; Zeller SL; Chen QY; Hong J; Luesch H
ACS Med Chem Lett; 2014 Aug; 5(8):905-10. PubMed ID: 25147612
[TBL] [Abstract][Full Text] [Related]
2. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.
Liu Y; Salvador LA; Byeon S; Ying Y; Kwan JC; Law BK; Hong J; Luesch H
J Pharmacol Exp Ther; 2010 Nov; 335(2):351-61. PubMed ID: 20739454
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases.
Cole KE; Dowling DP; Boone MA; Phillips AJ; Christianson DW
J Am Chem Soc; 2011 Aug; 133(32):12474-7. PubMed ID: 21790156
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere.
Pilon JL; Clausen DJ; Hansen RJ; Lunghofer PJ; Charles B; Rose BJ; Thamm DH; Gustafson DL; Bradner JE; Williams RM
Cancer Chemother Pharmacol; 2015 Apr; 75(4):671-82. PubMed ID: 25616967
[TBL] [Abstract][Full Text] [Related]
5. Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases.
Al-Awadhi FH; Salvador-Reyes LA; Elsadek LA; Ratnayake R; Chen QY; Luesch H
ACS Chem Neurosci; 2020 Jul; 11(13):1937-1943. PubMed ID: 32559056
[TBL] [Abstract][Full Text] [Related]
6. Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure-Activity Relationships.
Poli G; Di Fabio R; Ferrante L; Summa V; Botta M
ChemMedChem; 2017 Dec; 12(23):1917-1926. PubMed ID: 29117473
[TBL] [Abstract][Full Text] [Related]
7. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor.
Ying Y; Taori K; Kim H; Hong J; Luesch H
J Am Chem Soc; 2008 Jul; 130(26):8455-9. PubMed ID: 18507379
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of class I HDAC isoform selectivity of largazole analogues.
Kim B; Park H; Salvador LA; Serrano PE; Kwan JC; Zeller SL; Chen QY; Ryu S; Liu Y; Byeon S; Luesch H; Hong J
Bioorg Med Chem Lett; 2014 Aug; 24(16):3728-31. PubMed ID: 25070421
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Preliminary Biological Evaluation of Two Fluoroolefin Analogs of Largazole Inspired by the Structural Similarity of the Side Chain Unit in Psammaplin A.
Zhang B; Shan G; Zheng Y; Yu X; Ruan ZW; Li Y; Lei X
Mar Drugs; 2019 Jun; 17(6):. PubMed ID: 31163697
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors.
Diamond JR; Pitts TM; Ungermannova D; Nasveschuk CG; Zhang G; Phillips AJ; Bagby SM; Pafford J; Yacob BW; Newton TP; Tentler JJ; Gittleman B; Hartman SJ; DeMattei JA; Winkler JD; Wendt MK; Schiemann WP; Eckhardt SG; Liu X; Piscopio AD
Mol Cancer Ther; 2022 Mar; 21(3):397-406. PubMed ID: 34965958
[TBL] [Abstract][Full Text] [Related]
11. A fluorine scan on the Zn
Zhang B; Liu J; Gao D; Yu X; Wang J; Lei X
Eur J Med Chem; 2019 Nov; 182():111672. PubMed ID: 31505452
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of largazole analogues with modified surface recognition cap groups.
Bhansali P; Hanigan CL; Perera L; Casero RA; Tillekeratne LM
Eur J Med Chem; 2014 Oct; 86():528-41. PubMed ID: 25203782
[TBL] [Abstract][Full Text] [Related]
13. Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor.
Bowers A; West N; Taunton J; Schreiber SL; Bradner JE; Williams RM
J Am Chem Soc; 2008 Aug; 130(33):11219-22. PubMed ID: 18642817
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Biochemical Evaluation of Biotinylated Conjugates of Largazole Analogues: Selective Class I Histone Deacetylase Inhibitors.
Zhao L; Dunne CE; Clausen DJ; Roberts JM; Paulk J; Liu H; Wiest OG; Bradner JE; Williams RM
Isr J Chem; 2017 Apr; 57(3-4):319-330. PubMed ID: 30760938
[TBL] [Abstract][Full Text] [Related]
15. Unexpected Enhancement of HDACs Inhibition by MeS Substitution at C-2 Position of Fluoro Largazole.
Zhang B; Ruan ZW; Luo D; Zhu Y; Ding T; Sui Q; Lei X
Mar Drugs; 2020 Jun; 18(7):. PubMed ID: 32629787
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of largazole zinc-binding group analogs.
Kim B; Ratnayake R; Lee H; Shi G; Zeller SL; Li C; Luesch H; Hong J
Bioorg Med Chem; 2017 Jun; 25(12):3077-3086. PubMed ID: 28416100
[TBL] [Abstract][Full Text] [Related]
17. Total syntheses of the histone deacetylase inhibitors largazole and 2-epi-largazole: application of N-heterocyclic carbene mediated acylations in complex molecule synthesis.
Wang B; Huang PH; Chen CS; Forsyth CJ
J Org Chem; 2011 Feb; 76(4):1140-50. PubMed ID: 21244075
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Antiproliferative Activity of Nitric Oxide-Donor Largazole Prodrugs.
Borgini M; Zamperini C; Poggialini F; Ferrante L; Summa V; Botta M; Fabio RD
ACS Med Chem Lett; 2020 May; 11(5):846-851. PubMed ID: 32435394
[TBL] [Abstract][Full Text] [Related]
19. Largazole: from discovery to broad-spectrum therapy.
Hong J; Luesch H
Nat Prod Rep; 2012 Apr; 29(4):449-56. PubMed ID: 22334030
[TBL] [Abstract][Full Text] [Related]
20. Largazole Analogues Embodying Radical Changes in the Depsipeptide Ring: Development of a More Selective and Highly Potent Analogue.
Almaliti J; Al-Hamashi AA; Negmeldin AT; Hanigan CL; Perera L; Pflum MK; Casero RA; Tillekeratne LM
J Med Chem; 2016 Dec; 59(23):10642-10660. PubMed ID: 27809521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
